LH-RH antagonist Cetrorelix inhibits the growth of PC-3 through downregulation of EGF receptors whereas antiandrogen Flutamide affects the expression of protein kinase C (PKC) which is important for prostate cancer cell growth [23, 24]. The gene discussed is GNRH1; the disease is prostate carcinoma.